key: cord-1055725-xsg68kn6
authors: Stammes, Marieke A.; Lee, Ji Hyun; Meijer, Lisette; Flynn, JoAnne L.; Mani, Claudia; Crozier, Ian; Kuhn, Jens H.; Naninck, Thibaut; Doyle-Meyers, Lara A.; White, Alexander G.; Borish, H. Jacob; Hartman, Amy L.; Alvarez, Xavier; Ganatra, Shashank; Kaushal, Deepak; Bohm, Rudolf P.; le Grand, Roger; Scanga, Charles A.; Langermans, Jan A.M.; Bontrop, Ronald E.; Finch, Courtney L.
title: Medical imaging of pulmonary disease in SARS-CoV-2-exposed nonhuman primates
date: 2021-12-07
journal: Trends Mol Med
DOI: 10.1016/j.molmed.2021.12.001
sha: 42c1b8e070b9f0a656892da3a5ef7b69b366e724
doc_id: 1055725
cord_uid: xsg68kn6

Chest X-ray (CXR), computed tomography (CT), and positron emission tomography–computed tomography (PET-CT) are non-invasive imaging techniques widely used in human and veterinary pulmonary research and medicine. These techniques have recently been applied in studies of severe acute respiratory syndrome coronavirus 2-exposed (SARS-CoV-2-exposed) nonhuman primates (NHPs) to complement virologic assessments with meaningful translational readouts of lung disease. Our review of the literature indicates that medical imaging of SARS-CoV-2-exposed NHPs enables high-resolution qualitative and quantitative characterization of disease otherwise clinically invisible and potentially provides user-independent and unbiased evaluation of medical countermeasures. However, we also found high variability in image acquisition and analysis protocols among studies. These findings uncover an urgent need to improve standardization and ensure direct comparability across studies.

majority of human CXR examinations are inconclusive in the early stages of COVID-19 [37], 28 studies of SARS-CoV-2-exposed NHPs detected CXR abnormality early after exposure [9, [13] [14] [15] [16] [17] [20] [21] [22] [23] 26, 27, 29, 32, 35, [44] [45] [46] [47] . However, CXR imaging was inconclusive in other studies [12, 13, [23] [24] [25] 28] and was generally found to be uncorrelated to the degree of lung abnormalities at necropsy (Figure 1 ).

Although consensus guidelines [1, 10, 11] have not clearly defined the relative merits of CXR versus CT imaging in assessing COVID-19, chest CT is recommended for the evaluation of COVID-19 patients, typically to inform clinical management in severely ill or deteriorating patients, including the exclusion of other diagnoses, e.g., pulmonary embolism. CT imaging has been applied in 16 published studies of SARS-CoV-2-exposed NHPs (Table 1 ) [48] . As a tomographic imaging modality that acquires data in three dimensions and at higher resolution than CXR, chest CT is more sensitive and affords more detailed qualitative and quantitative characterization of lung abnormalities [38] . The risks and benefits associated with chest CT versus CXR are only partly applicable to NHPs in a research setting: higher radiation exposure has less consequence because most studies are terminal; staff in contact with research animals are always in biosecure personal protective equipment; and potential contamination of imaging suites is mitigated by scheduled rigorous decontamination. [1, 49] .

In NHP studies, CT imaging generally mirrored imaging of human lung abnormalities both in character and distribution. The reported prevalence of common CT findings in SARS-CoV-2exposed NHPs is shown in Table 1 and Figure 2 . Compared to human disease, CT abnormalities (most commonly GGOs) in NHPs were detected at a much earlier disease stage and resolved fairly rapidly, albeit with considerable inter-subject heterogeneity; most abnormalities were first observed starting at 2 d post-exposure and resolved within 2 weeks

[33].

Journal Pre-proof CXR and chest CT are mainly anatomical imaging modalities that provide structural characterization, i.e., the location, volume, morphology, and texture of lung abnormality. In contrast, PET-CT combines the high-resolution anatomical information from CT with quantitative functional assessments by PET. When performed with the metabolic radiotracer [fluorine-18]fluoro-2-deoxyglucose ( 18 F-FDG); a glucose analog that is internalized but not metabolized by metabolically active inflammatory cells), PET-CT has enabled the quantification of heightened metabolic activity as a proxy of inflammation in lung parenchyma, regional lymph nodes, heart, kidneys, bone marrow, brain, and other organs in the context of COVID-19 [8, 9, [50] [51] [52] . However, its limited availability in many countries and emergency settings have restricted the application of PET-CT as a frontline COVID-19 diagnostic imaging modality in the clinic. In pre-clinical research settings, PET-CT is being increasingly used in NHP studies to evaluate human respiratory diseases, most notably tuberculosis [53] . However, even in pre-clinical settings, this imaging modality is not widely available in biocontainment laboratories; PET-CT imaging has been used in only six studies of SARS-CoV-2-exposed NHPs (Table 1 and Figure 1 ) [8, 9, 34, [50] [51] [52] . Other imaging modalities can be applied in both human and NHPs for diagnosis of COVID-19 (see Text Box 2 -Other imaging techniques).

Reliable quantification of lung abnormalities identified by in vivo imaging within (and among) experimental NHP groups is of great interest to allow meaningful correlations with histopathological data and for the evaluation of both therapeutic and prophylactic treatment efficacy [8, 33, 35, 50, 54, 55] . Although data continue to accumulate, COVID-19-related lung abnormalities detected by CT have already been successfully matched with gross pathology of J o u r n a l P r e -p r o o f Journal Pre-proof NHP samples (Figure 3 ). Several semi-quantitative scoring systems based on lesion volume and type (e.g., GGOs, consolidation, crazy-paving pattern, and pleural thickening) have been developed to allow monitoring of disease progression by lung CT of NHPs (Table 1) . These scores reflect the extent and longitudinal course of qualitative findings. However, poor scoring standardization across studies makes it challenging to compare experimental data from different research groups in detail outside the determination of a general pattern and peak. Recognizing that semi-quantitative scoring relies on qualitative radiological assessments potentially subject to bias, several research groups have invested in the development of semi-automated, user-independent, quantitative readouts of radiographic abnormalities. For instance, normalized changes from pre-exposure baselines can be measured longitudinally as the percent change in lung hyperdensity (PCLH) [56] using CT data ( Figure 4 ) [8, 33] . Further development of such quantitative readouts should be encouraged.

A limited number of NHP studies have used PET-CT to measure 18 F-FDG uptake as a proxy for metabolic activity in the lungs and regional lymph nodes via anatomical co-registration with CT. Average, maximum, or peak (as robust alternative to maximum values which could be affected by noise) standard uptake values (SUVs) in lung lesions, lymph nodes, or total lungs were used as measures of 18 F-FDG uptake and as surrogates of inflammatory activity. 18 F-FDG uptake was generally found to co-register with CT-identified structural

Medical imaging of SARS-CoV-2-exposed NHPs is providing deeper insight into the pathophysiological processes related to lung abnormalities in COVID-19 patients. Indeed, the majority of clinical disease would be inapparent by clinical assessment (observation, physical examination, and laboratory blood markers), which justifies higher resolution imaging evaluation. However, many challenges need to be surmounted before non-invasive imaging readouts of the lungs can be reliably used as COVID-19 markers and to fully exploit their potential complement to standard immunological and virologic assays. Some of these challenges are related to the NHP model. The clinical disease elicited by SARS-CoV-2 exposure in NHPs is generally mild-to-moderate (even radiographically), though some abnormalities associated with more severe disease (e.g., alveolar consolidation) have been reported occasionally [8, 22, 45, 50, 52, [57] [58] [59] [60] . Mild-to-moderate disease progression in NHPs mirrors that observed in humans, e.g., in the evolution of initial GGOs to organizing pneumonia and consolidation. Unsurprisingly in (typically) young healthy animals without significant co-morbidity, consistent radiographic abnormalities associated with acute respiratory distress syndrome (ARDS) in humans are absent, and the model has failed to assist in the evaluation of more serious lung pathology. Since COVID-19 severity in humans (and therefore also likelihood of hospitalization) has been associated with several risk factors, (Table 1) weighed less than 10 kg; therefore, the effect of obesity on NHP disease progression has yet to be addressed.

The SARS-CoV-2 exposure route may also be a factor influencing lung abnormality pattern and severity in NHPs. NHPs have been exposed to SARS-CoV-2 in various ways, most commonly via combined intranasal and intratracheal inoculation [12, 22, 27, 35, 50, 51, 54, 55, [57] [58] [59] [67] [68] [69] . Multiple routes [9, 13, 16, 20, 23, 26, 28, 29, 31, 33, 34, 46] lead to SARS-CoV-2

shedding. But, although infection is not necessarily dependent on respiratory tract exposure, it is plausible that the route of exposure impacts the progression of disease. As presented in Table 1 , exposure deeper in the trachea was found to induce lung lesion development earlier compared to exposure in the upper trachea [9,50,55,57,67]. Small-particle aerosol exposure is an alternative to direct inoculation [9,32,34,44]. Overall, viral load, clinical disease progression and severity, plasma cytokine concentrations, and pathology are similar in aerosol-exposed NHPs compared to those exposed via other routes [34] . Since SARS-CoV-2 particles are approximately 100-120 nm in diameter, aerosols with droplet sizes of 1-3 µm have the potential to contain up to 120-460 virions per droplet [70] . The half-maximum infection dose (ID 50 ) of SARS-CoV-2 is unknown for both humans and NHPs but is likely to be less than 400 virions, which is the ID 50 of SARS-CoV [71]. These numbers suggest that one droplet may suffice to initiate infection. Studies to determine the impact of aerosol particle size on the pulmonary disease phenotype (quality and quantity) are ongoing. imaging [12, 13, 15, 16, 20, [22] [23] [24] [27] [28] [29] [30] 33, 35, 47, 51, 52, 54, 55, 57, 59, 67, 75, 76] . Eight included single BAL just prior to or at necropsy [12, 20, 22, 33, 55, 58, 67, 75] . In one study, chest opacities and abnormalities might have been caused by the BAL procedure [12] . In two studies, BAL was deliberately not performed due to concerns of interference with imaging [8, 50] . To guard against confounding findings due to BAL, medical imaging and necropsies should be performed on days not consecutive with BAL [74].

Additionally, incorporating quantitative, longitudinal medical imaging in high animal biosafety level (ABSL-3) or maximum containment settings (ABSL-4), as required for research with SARS-CoV-2 [77], is not without challenges, including: increased experimental costs; medical imaging equipment is not routinely available in most ABSL-3 and -4 settings; the maximum frequency of applied anesthesia required for imaging and the maximum number of NHPs that can practically be imaged at a single time point may create bottlenecks that limit optimal experimental design; imaging conditions and technology vary among studies and sites, which makes it challenging to directly compare data obtained at separate sites (as highlighted in our review). We foresee that advanced medical imaging of SARS-CoV-2exposed NHPs may be greatly enhanced by the development of best-practice principles and knowledge of imaging NHPs focused on, though not solely applicable for, SARS-CoV-2 infection, are enumerated in Table 2 A limited number of human observational studies or clinical trials [79] have used medical imaging as part of the evaluation of treatment efficacy, including evaluations of tocilizumab (CT/CXR, qualitative) [80, 81] , favipiravir (CT, semiquantitative score), convalescent plasma (CT, qualitative) [82] , and hydroxychloroquine versus febuxostat (CT, percent involvement) [83] . Generally, these have relied, at best, on semi-quantitative CT scoring systems as secondary outcomes and often report only qualitative pre-/post-treatment changes. With regard to evaluation of therapeutic and prophylactic treatment efficacy in NHPs, a limited number of studies have been performed [84] . A recent study evaluating the efficacy of dalbavancin in rhesus monkeys resulted in fewer pulmonary infiltrates detectable by CXR in treated versus non-treated animals [85] . Other studies have instead relied on the characterization of CXR abnormalities using standard scoring systems. In the evaluation of remdesivir [20] and baricitinib [22] in rhesus monkeys, this approach was able to capture significant differences in lung involvement between treatment and control groups; however, in another study, no difference between groups could be observed by in vivo imaging despite detection of a treatment effect by lung pathology scores. An efficacy evaluation of hydroxychloroquine (either alone or in combination of azithromycin) in SARS-CoV-2exposed crab-eating macaques used a semi-quantitative CT score, compounding information on lesion type and volume, and found no evidence of antiviral activity or clinical benefit (as confirmed by recent meta-analyses) [57, 86] .

Recognizing that expert-generated qualitative or semi-quantitative scoring systems ( improve the diagnosis of neuroendocrine tumors [96] . However, because SSTR2 is expressed by several inflammatory cells, DOTATATE is being investigated as a potential tracer for evaluation of several conditions, including cardiovascular [97] and infectious diseases [98] , and seems to be particularly advantageous for imaging cardiac inflammation [94] . In one case report, DOTATATE was detected in an axillary lymph node after COVID-19 vaccination [99, 100] . PET radiotracers targeted to the ACE2 receptor are also being developed [101] .

Further in-depth studies investigating the expression levels of imaging target molecules in key cellular populations (e.g., macrophages) may prove invaluable in shaping the future landscape of PET-CT imaging in the context of COVID-19 [102] .

Here we provided a detailed review of medical imaging in NHP models of COVID-19. Our search was limited to studies of medical imaging in SARS-CoV-2-exposed NHPs published online and found within online repositories. A number of studies were limited in terms of sample size, data availability, and methodologic quality, and the reported findings should be interpreted within that context. Nevertheless, these studies reflect current approaches. We argue that advanced imaging tools add unique insight into (so far) poorly understood relationships of SARS-CoV-2 exposure, infection, the host's response, and disease J o u r n a l P r e -p r o o f Journal Pre-proof presentation in the lungs. Challenges to advanced imaging characterization in NHP models require careful consideration and upstream investment that is likely well worth the return, not just in the current moment (for SARS-CoV-2/COVID-19) but in the longer term for numerous respiratory viruses and diseases, known or yet unencountered. Careful characterization of NHP models may enable exploration of complex determinants and progression of disease (see Outstanding Questions). Advanced medical imaging of adequate resolution is of importance to truly characterize (quality) and reliably measure (quantity) disease without bias to understand and provide meaningful longitudinal readouts of disease (in animal studies) and bridge to humans; thus, medical imaging will be an increasingly important component of the NHP modelers' toolkit. To be able to judge these results it is essential to know in what way animal models, in here NHPs, reproduce the phenotype of a human symptomatic SARS-CoV-2 infection.

The clinical manifestations of SARS-CoV-2 infection observed in NHP models have included fever, weight loss, loss of appetite, pale appearance, dehydration, diarrhea, and nasal discharge. These signs are comparable to the spectrum of clinical symptoms detected in humans and associated with mild disease. Similar to humans for mild disease, no differences were consistently observed between males and females or young and old macaques. However, with respect to disease progression leading to severe and critical disease this is, so far, only detected in two NHPs and is in contrary to clinical findings in humans in which age has its impact on disease progression [34].

In NHPs, viral replication was mainly observed in the respiratory tract (nasal cavity, oropharynx, and lungs) and in the gastrointestinal system. At necropsy, lungs showed mild-tomoderate interstitial pneumonia and swollen lymph nodes. For human viral replication is most In short, current NHP models of COVID-19 (rhesus monkeys, crab-eating [cynomolgus] macaques, grivets/vervets, and common marmosets) recapitulate mild-to-moderate disease in humans in both clinical and radiological presentation, with findings of more severe lung pathology and fatality absent [18-20,31,39,60, [105] [106] [107] [108] [109] [110] .

Besides CXR, CT, and PET-CT, other imaging techniques are used for visualizing the lungs in NHPs exposed to SARS-CoV-2. In the clinic, ultrasound is commonly used for the diagnosis of pneumonia and to evaluate the integrity of the pleural space [37, 111] . In COVID-19, ultrasound detected B-lines, consolidations, GGOs, and pleural thickening, and diagnostic accuracy was found to increase with disease severity [37, 111] . However, the presence of air in non-affected lung parenchyma can impair the assessment of deeper parenchymal abnormalities [37], making it difficult to use this imaging modality to assess lung involvement in SARS-CoV-2-exposed NHPs. Additionally, inter-operator and inter-reader variability make standardization challenging. Thus far, ultrasound imaging has only been used in a single SARS-CoV-2-related NHP study-which concluded that ultrasound sensitivity to detect lung abnormalities was high, whereas the diagnostic efficacy for mild-to-moderate disease was found to be relatively low [69] . With the drawbacks outweighing the advantages, ultrasound is not likely to gain useful traction in evaluating SARS-CoV-2-exposed NHPs.

Another often used clinical imaging modality is magnetic resonance imaging (MRI). MRI has been used for evaluation of COVID-19 patients, primarily for examination of neurologic complications. MRI is appealing for longitudinal imaging because of the lack of exposure to ionizing radiation. However, artefacts from cardiorespiratory motion and the intrinsically low Although not the primary imaging modality of choice, the signs of interstitial pneumonia can nevertheless be detected by MRI [112, 113] . The application of specific non-contrast or contrast-enhanced MR sequences [114] [115] [116] [117] has been investigated in clinical research settings (outside of infectious diseases) to provide free-breathing, high-resolution evaluation of lung anatomy and ventilation. Furthermore, hyperpolarized MRI using [ 129 Xe] has been used to detect gas-blood exchange defects in COVID-19 patients [118, 119] .

The last imaging modality discussed in this text box is a different CT technique than the conventional CT in which two datasets with different x-ray spectra are generated, called dualenergy CT (DECT). DECT is a form of quantitative CT and has been used, with iodine as contrast agent, in evaluation of COVID-19 patients to provide quantitative assessment of lung perfusion and detection of vascular abnormalities, including pulmonary embolism [120] [121] [122] [123] [124] .

This technique was able to detect lung vascular impairment even in asymptomatic COVID-19 patients [121] , thereby holding promise for the evaluation of these parameters in the mild-tomoderate NHP model. Table 2 . Key principles and recommendations for imaging of SARS-CoV-2-exposed NHPs

Modality CXR: low sensitivity and reader-dependence limits utility of CXR in a mild-to-moderate infection model. LUS: high sensitivity, visibility of centrally located lesions is limited due to aeration which limits its utility in a mild-to-moderate infection model. CT: the recommended modality for the detection of pulmonary abnormalities in SARS-CoV-2-exposed NHPs. PET-CT: provides limited additional value for the detection of lung abnormalities compared to a CT (with 18 F-FDG), high value for the functional characterization and quantification of LNs.

Obtain a baseline image before infection.

Minimal imaging frequency after infection, one image in the first 4 d post-exposure, one in Day 5 through Day 10 and one in Day 11 through Day 15.

Imaging frequency can be reduced but not stopped at 14 d post-exposure.

Qualitative evaluation of the extent, distribution, type, and evolution of abnormality by expert readers is sufficient for a general conclusion. Quantitative analysis is preferred preferably in an automated and user-independent manner. In general, quantification of the percentage of lung involvement, independent of the type of abnormality has been useful.

The appearance of lung lesions should be correlated with the gross pathology score but not necessarily RT-PCR values obtained from upper or lower respiratory tract sampling. Other experimental procedures in the lungs (e.g., BAL) can influence the appearance of lung lesions both during imaging and necropsy. CXR = chest X-ray LUS = lung ultrasound CT = computed tomography SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2 NHP = nonhuman primate PET = positron emission tomography 18 

The role of chest imaging in patient management during the COVID-19 pandemic: a multinational consensus statement from the Fleischner Society

Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19)

Correlation of chest CT and RT-PCR testing for coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases

Animal models of mechanisms of SARS-CoV-2 infection and COVID-19 pathology

ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities

Animal models for COVID-19

Animal models of COVID-19. I. Comparative virology and disease pathogenesis

Characteristic and quantifiable COVID-19-like abnormalities virus from both respiratory and gastrointestinal tracts

Radiological Society of North America expert consensus statement on reporting chest CT findings related to COVID-19. Endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNAsecondary publication

Radiological Society of North America expert consensus document on reporting chest CT findings related to COVID-19: endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA

Establishment of an African green monkey model for COVID-19 and protection against re-infection

Single-cell RNA sequencing reveals SARS-CoV-2 infection dynamics in lungs of African green monkeys

UK B.1.1.7 (Alpha) variant exhibits increased respiratory replication and shedding in nonhuman primates

The gastrointestinal tract is an alternative route for SARS-CoV-2 infection in a nonhuman primate model

Early post-infection treatment of SARS-CoV-2 infected macaques with human convalescent plasma with high neutralizing activity reduces lung inflammation. bioRxiv

Safety, immunogenicity and protection provided by unadjuvanted and adjuvanted formulations of recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in non-human primates. bioRxiv

Age-related differences in immune dynamics during SARS-CoV-2 infection in rhesus macaques

The pigtail macaque (Macaca nemestrina) model of COVID-19 reproduces diverse clinical outcomes and reveals new and complex signatures of disease. bioRxiv

Comparison of nonhuman primates identified the suitable model for COVID-19

Development of a Coronavirus Disease 2019 Nonhuman Primate Model Using Airborne Exposure

An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates

Analysis of 18FDG PET/CT imaging as a tool for studying Mycobacterium tuberculosis infection and treatment in non-human primates

COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models

2020) mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection. bioRxiv

New image analysis technique for quantitative longitudinal assessment of lung pathology on CT in infected rhesus macaques

Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates

Immunological and pathological outcomes of SARS-CoV

Interferon therapy in patients with SARS, MERS, and COVID-19: A systematic review and meta-analysis of clinical studies

Promising effects of tocilizumab in COVID-19: A noncontrolled, prospective clinical trial

Tocilizumab effects in COVID-19 pneumonia: role of CT texture analysis in quantitative assessment of response to therapy

The efficacy assessment of convalescent plasma therapy for COVID-19 patients: a multi-center case series

Febuxostat therapy in outpatients with suspected COVID-19: A clinical trial

Experimental treatment with favipiravir for COVID-19: an openlabel control study

Dalbavancin binds ACE2 to block its interaction with SARS-CoV-2 spike protein and is effective in inhibiting SARS-CoV-2 infection in animal models

Hydroxychloroquine plus standard of care compared with standard of care alone in COVID-19: a meta-analysis of randomized controlled trials

Current status and future prospects of PET-imaging applications in patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs)

Detection of atherosclerotic inflammation by 68 Ga-DOTATATE PET compared to [ 18 F]FDG PET Imaging

Cu-DOTATATE positron emission tomography (PET) of Borrelia burgdorferi infection: in vivo imaging of macrophages in experimental model of lyme arthritis

DOTATATE uptake in an axillary lymph node after COVID-19 vaccination

Supraclavicular and axillary lymphadenopathy induced by COVID-19 vaccination on 18 F-fluorthanatrace, 68 Ga-DOTATATE, and 18 Ffluciclovine PET/CT

Molecular PET/CT Profiling of ACE2 Expression In Vivo: Implications for Infection and Outcome from SARS-CoV-2

Discovery of potential imaging and therapeutic targets for severe inflammation in COVID-19 patients

SARS-CoV-2 infection protects against rechallenge in rhesus macaques

Characteristic and quantifiable COVID-19-like abnormalities in CT-and PET/CT-imaged lungs of SARS-CoV-2-infected crab-eating macaques (Macaca fascicularis)

Development of an inactivated vaccine candidate for SARS-CoV-2

Respiratory disease and virus shedding in rhesus macaques inoculated with SARS-CoV-2

ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

The role of imaging and other diagnostic approaches in COVID-19

An Incidental Diagnosis of SARS-CoV-2 Pneumonia With Magnetic Resonance Imaging

Discrepancies in the clinical and radiological profiles of COVID-19: A case-based discussion and review of literature

A study of the correlation of perfusion parameters in highresolution GRASP MRI with microvascular density in lung cancer

Simultaneous evaluation of lung anatomy and ventilation using 4D respiratory-motion-resolved ultrashort echo time sparse MRI

Free-breathing dynamic contrast-enhanced MRI for assessment of pulmonary lesions using golden-angle radial sparse parallel imaging

Hyperpolarized 129 Xe MRI abnormalities in dyspneic patients 3 months after COVID-19 pneumonia: preliminary results

Damaged lung gas exchange function of discharged COVID-19 patients detected by hyperpolarized 129 Xe MRI

Severe COVID-19 pneumonia: Perfusion analysis in correlation with pulmonary embolism and vessel enlargement using dual-energy CT data

Case studies in physiology: temporal variations of the lung parenchyma and vasculature in asymptomatic COVID-19 pneumonia: a multispectral 123. Ridge

Quantitative CT imaging and advanced visualization methods: potential application in novel coronavirus disease 2019 (COVID-19) pneumonia

Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in Rhesus macaques

Rapid protection from COVID-19 in nonhuman primates vaccinated intramuscularly but not intranasally with a single dose of a recombinant vaccine

2020) mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection

COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models

Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates

We acknowledge the assistance of Anya Crane (Integrated Research Facility All authors agreed to submit the manuscript, read, and approved the final draft and take full responsibility of its content, including the accuracy of the data and the fidelity of the work performed.

The authors declare no competing interests.